Loading...
•
Jun 30, 2023
Janux Q2 2023 Earnings Report
Reported second quarter 2023 financial results and business highlights.
Key Takeaways
Janux Therapeutics reported positive interim Phase 1 clinical trial data for PSMA-TRACTr JANX007 in prostate cancer, strengthened their management team, and had $303.3 million in cash, cash equivalents, and short-term investments at the end of the second quarter 2023. They further strengthened their balance sheet with an approximately $60 million offering in July.
Presented positive interim Phase 1 clinical trial data for PSMA-TRACTr JANX007 in prostate cancer.
Management team bolstered with the appointment of Dr. Zachariah McIver as Vice President, Clinical Development.
Reported $303.3 million in cash, cash equivalents, and short-term investments at the end of the second quarter 2023.
Strengthened balance sheet with approximately $60 million offering in July.
Revenue by Segment
Forward Guidance
Janux plans to deploy the funds raised in July to advance another program into clinical trials and advance additional preclinical programs.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...